VFA
CELGZ

Virtus Fund Advisers’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Virtus Fund Advisers’s Portfolio CELGZ Stock Details CELGZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-14
Closed – – 880
2015
Q4 		$0 Hold
14
– – ﹤0.01% 889
2015
Q3 		$0 Buy
+14
New +$27 ﹤0.01% 905

Other funds holding CELGZ

CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
FA
FCG Advisors Chatham, New Jersey $425M AUM 12.09% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Virtus Fund Advisers's CELGZ Position: Q1 2016 in Review

Virtus Fund Advisers sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q1 2016, closing a stake of 14 shares.

Virtus Fund Advisers first reported a position in CELGZ in Q3 2015 and held it in 2 quarters. The position peaked at $0 in Q4 2015. 25 funds tracked by Wall St. Rank hold CELGZ as of Q1 2016.

  • Virtus Fund Advisers reported no remaining Celgene Corporation Contingent Value Rights position as of Q1 2016 after selling out during the quarter.
  • Virtus Fund Advisers sold 14 Celgene Corporation Contingent Value Rights shares in Q1 2016.
  • Virtus Fund Advisers first reported a position in Celgene Corporation Contingent Value Rights in Q3 2015 and held it in 2 quarters.
  • Virtus Fund Advisers's Celgene Corporation Contingent Value Rights position peaked at $0 in Q4 2015.
  • 25 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q1 2016.

Based on Virtus Fund Advisers's 13F filing for Q1 2016, filed 11 May 2016.